ZYBERNO
Stock Report
Updated Sep 1, 2026

BioCorRx Inc. (BICX)

Healthcare • OTC

$0.21

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
BioCorRx Inc. (BICX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-229.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

BioCorRx Inc. (BICX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.21
Market Cap:$6.23M

Valuation Multiples (2)

P/S Ratio:7.81x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$13.06M

Price Action & Momentum (3)

Momentum Percentile:31 / 100
% of 52-Week High:16.4%
B. Profitability Assessment

Return Metrics (4)

ROA:-107.3%
Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-2.3%

Margin Analysis (1)

Ebitda Margin:-704.4%

Yield Metrics (2)

Earnings Yield:-$157.89
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:72.4%
Latest Earnings Filed:2026-08-14

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):44.8%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.07x
Quick Ratio:0.07x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-16.59x
Times Interest Earned:-16.59

Capital Structure (4)

Working Capital:-8,231,326.00
Cash And Cash Equivalents:21,237.00
Long Term Debt:$92.72K
Net Debt:$6.83M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $797.24K
Linear Growth: 44.8%
📊 Click to view full BICX Revenue analysis & methodology →
Cost Of Revenue Ttm:$1.67K

Profitability Breakdown (2)

Gross profit TTM: $795.58K
Linear Growth: 33.6%
📊 Click to view full BICX Gross Profit analysis & methodology →
-$5.78M

Bottom Line Performance (3)

-$4.95M
Income Before Tax:-$4.05M
Ebitda Ttm:-5,616,053.00

Operating Expenses (5)

Operating Expenses:6,897,016.00
R And D Expense:2,366,237.00
Sga Expense:3,830,450.00
Income Tax Expense:$0.00
Interest Expense:291,206.00

Expense Ratios (3)

R And D To Revenue Percentage:2,689.8%
Sga To Revenue Percentage:4,354.3%
Ebitda Margin:-704.4%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.91M
Current Assets:$623.38K
Ppe Net:194,551.00
Goodwill:563,158.00
Intangible Assets:$541.12K

Liability Structure (4)

Total Liabilities:14,379,077.00
Current Liabilities:8,854,703.00
Long Term Debt:$92.72K
Short Term Debt:$6.76M

Equity & Capital (3)

Equity:-$12.47M
Retained Earnings:-$88.56M
Common Stock:750,000,000.00

Working Capital Items (3)

Accounts Receivable:67,694.00
Inventory:43,551.00
Accounts Payable:4,439,572.00

Special Items (2)

Contract Liabilities:1,040.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.30M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$505.52K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:700,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:164,992.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.81
-$0.24
Earnings Per Share Ttm:-$0.17

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.03
Operating Cash Flow Per Share:-$0.08

Book Value & Capital (2)

Book Value Per Share:-$0.42
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.17x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:11.78x
Days Sales Outstanding Ttm:30.99

Inventory Management (2)

Inventory Turnover Ttm:0.04x
Days Inventory Outstanding Ttm:9,535.76

Payables & Cash Cycle (2)

Days Payable Outstanding:972,071.85
Cash Conversion Cycle:-962,505.10
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.0%
Fundamental Growth Rate (g):-2.3%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):44.8%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):33.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:BICX
Company Name:BioCorRx Inc.
Sector:Healthcare
Industry:Services-Specialty Outpatient Facilities, NEC
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:29.67M
Shares Outstanding Basic:29.67M
Shares Outstanding Diluted:29.22M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 15:02:03 UTC
Data Timestamp:2026-08-21T14:24:36.109819
Scroll to Top